
- Prostate Cancer Special Issue
- Volume 1
- Issue 1
Medical Illustration: Prostate Cancer
When diagnosing prostate cancer, doctors consider staging and grading. In grading, a score is assigned based on the Gleason grading system.
STAGE 1: The cancer is located on one side of the prostate. At this stage, the tumor is very small or found incidentally, possibly during surgery or by an elevated prostate-specific antigen (PSA) level. The Gleason score is low.
STAGE 2: The cancer is located only in the prostate but can be seen on imaging scans or felt during a digital rectal exam. The Gleason score may range from 2 to 10.
STAGE 3: The cancer has extended through the outer layer of the prostate and into surrounding tissues and may be found in the seminal vesicle but not in the lymph nodes. The Gleason score may range from 2 to 10.
STAGE 4: The cancer has spread to the lymph nodes near or far from the prostate or has spread to distant tissues or organs, such as the liver or bones. The Gleason score may range from 2 to 10.
CLICK TO DOWNLOAD/ENLARGE The Gleason grading system defines prostate cancer by grade based on the pathologist’s review of a biopsy or surgical specimen, with 1 being the least aggressive and 5 being the most aggressive. The grade of the most common tumor pattern is added to the grade of the second most common tumor pattern in the tissue examined to create the Gleason score. A Gleason score of 2 to 4 is considered low grade, 5 to 7 is intermediate grade and 8 to 10 is high grade.
Articles in this issue
about 10 years ago
Choosing the Right Pathabout 10 years ago
Resolving a Controversy: The Value of PSA Screeningabout 10 years ago
Where Are the Men? BRCA Mutations and Male Awarenessabout 10 years ago
Surgery or Radiation for Prostate Cancer: What Determines the Choice?about 10 years ago
Marathon Men: Living Longer With Prostate Cancerabout 10 years ago
Delicate Difference: More Surgical Options for Prostate Cancerabout 10 years ago
Satisfaction Guaranteed: Sexual Activity After Prostate Cancer Therapyabout 10 years ago
On Guard: Gauging Aggressiveness of Prostate Cancer Aids Decision Making